米尔菲尔中风

我们的临床兴趣在于治疗急性中风，增强康复能力和预防复发。以下多中心试验由卒中试验组的Philip Bath和Nikola Sprigg协调进行，住院前超急性降血压（RIGHT试验），超急性降温/低温治疗（EU FP-7试验），超急性氨甲环酸用于原发性脑内出血（HTA TICH-2试验），医院急性降压（三硝酸甘油酯的MRC ENOS试验），预防早期复发的急性强化抗血小板药物（BHF-HTA TARDIS试验），预防中风后认知障碍（TSA-AS PODCAST试验） ），内源性干细胞的长期动员（RfPB ST
Our clinical interests are in the treatment of acute stroke, enhancing recovery and preventing recurrence. The following multicentre trials are coordinated by Philip Bath and Nikola Sprigg from the Stroke Trials Unit Ultra-acute lowering of blood pressure before hospitalisation (RIGHT trial), Hyperacute cooling/hypothermia (EU FP-7 trial), Hyperacute tranexamic acid for primary intracerebral haemorrhage (HTA TICH-2 trial), Acute lowering of BP in hospital (MRC ENOS trial of glyceryl trinitrate), Acute intensive antiplatelets for preventing early recurrence (BHF-HTA TARDIS trial), Prevention of post stroke cognitive impairment (TSA-AS PODCAST trial), Chronic mobilisation of endogenous stem cells (RfPB STEMS-3 trial of granulocyte colony stimulating factor).